Loading clinical trials...
Loading clinical trials...
A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Conditions
Interventions
Samidorphan + olanzapine (ALKS 3831)
Placebo + olanzapine
Locations
71
United States
Alkermes Investigational Site
Little Rock, Arkansas, United States
Alkermes Investigational Site
Springdale, Arkansas, United States
Alkermes Investigational Site
Anaheim, California, United States
Alkermes Investigational Site
Culver City, California, United States
Alkermes Investigational Site
Garden Grove, California, United States
Alkermes Investigational Site
Irvine, California, United States
Start Date
May 1, 2014
Primary Completion Date
January 11, 2017
Completion Date
February 1, 2017
Last Updated
October 8, 2021
NCT06894212
NCT07027839
NCT06003036
NCT06552741
NCT04226898
NCT07279558
Lead Sponsor
Alkermes, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions